Abstract:Recently, mixed-ligand copper(II) complexes have received much attention in searching for alternative metallodrugs to cisplatin. A series of mixed ligand Cu(II) complexes of the type [Cu(L)(diimine)](ClO4) 1-6, where the HL is 2-formylpyridine-N4-phenylthiosemicarbazone and the diimine is 2,2'-bipyridine (1), 4,4'-dimethyl-2,2'-bipyridine (2), 1,10-phenanthroline (3), 5,6-dimethyl-1,10-phenanathroline (4), 3,4,7,8-tetramethyl-1,10-phenanthroline (5) and dipyrido-[3,2-f:2',3'-h]quinoxaline (6), has been synthesized and their cytotoxicity in HeLa cervical cancer cells examined. In the molecular structures of 2 and 4, as determined by single-crystal X-ray studies, Cu(II) assumes a trigonal bipyramidal distorted square-based pyramidal (TBDSBP) coordination geometry. DFT studies reveal that the axial Cu-N4diimine bond length, interestingly, varies linearly with the experimental CuII/CuI reduction potential as well as the trigonality index τ of the five-coordinate complexes, and that methyl substitution on diimine co-ligands tunes the extent of the Jahn-Teller distortion at the Cu(II). While 4 is involved in strong DNA groove binding with a hydrophobic interaction of methyl substituents, 6 is involved in stronger binding through partial intercalation of dpq with DNA. Complexes 3, 4, 5, and 6 efficiently cleave supercoiled DNA into NC form in ascorbic acid by generating hydroxyl radicals. Interestingly, 4 exhibits higher DNA cleavage in hypoxic than at normoxic conditions. Notably, except for [CuL]+, all the complexes were stable in 0.5% DMSO-RPMI (without phenol red) cell culture medium up to 48 h at 37 °C. Remarkably, all the complexes show time-dependent cytotoxicity at nanomolar concentrations (IC50, 7.0-182 nM) in HeLa cervical cancer cells compared with uncoordinated ligand HL (IC50 > 10 000 nM). Except for 2 and 3, all the complexes exhibit higher cytotoxicity than [CuL]+ at 48 h. 4 shows (57.2 nM) higher cytotoxicity than 1 (181.5 nM) at 24 h incubation; however, notably, 1 demonstrates phenomenal cytotoxicity (7.0 nM) higher than 4 (13.6 nM) at 48 h incubation. The selectivity index (SI) reveals that complexes 1 and 4 are 53.5 and 37.3, respectively, times less toxic to HEK293 normal cells than to cancerous cells. Except for [CuL]+, all the complexes generate ROS to different extents at 24 h, with 1 producing the highest amount, which is consistent with their redox properties. Also, 1 and 4 exhibit, respectively, sub-G1 and G2-M phase cell arrest in the cell cycle. Therefore, complexes 1 and 4 have the potential to emerge as promising anticancer agents.

Indium(III) complexes with lapachol: cytotoxic effects against human breast tumor cells and interactions with DNA

Strong in vitro anticancer activity of copper(ii) and zinc(ii) complexes containing naturally occurring lapachol: cellular effects in ovarian A2780 cells

Palladium(II) Complexes with N,N′-Dialkyl-1,10-phenanthroline-2,9-dimathanamine: Synthesis, Characterization and Cytotoxic Activity

Mixed ligand copper(II)-diimine complexes of 2-formylpyridine- N4-phenylthiosemicarbazone: diimine co-ligands tune the in vitro nanomolar cytotoxicity

“Antibacterial properties of nine indium(III) complexes of substituted pyrazoles/pyrazolate and the structural and solution characterization of the mer- and trans‐indium(III) complexes of 4-Me-pzH”

Synthesis and Biological Activity of Binuclear Platinum Complexes Containing Two Monofunctional Cis-[Pt(Nh3)(2)Cl](+) Units Bridged by 4,4 '-Dipyridyl Selenides or Sulfides

Synthesis, characterization and cytotoxicity of lanthanum(III) complexes with novel 1,10-phenanthroline-2,9-bis-α-amino acid conjugates

A series of DNA targeted Cu (II) complexes containing 1,8-naphthalimide ligands: Synthesis, characterization and in vitro anticancer activity

Antitumor copper(II) complexes with hydroxyanthraquinones and N,N-heterocyclic ligands

Investigation of the complex structure, comparative DNA-binding and DNA cleavage of two water-soluble mono-nuclear lanthanum(III) complexes and cytotoxic activity of chitosan-coated magnetic nanoparticles as drug delivery for the complexes

Half-sandwich Iridium N-heterocyclic Carbene Anticancer Complexes

Synthesis, DNA binding, cellular DNA lesion and cytotoxicity of a series of new benzimidazole-based Schiff base copper(II) complexes

Iridium(III) coordination compounds based on organophosphorus ancillary ligands showing cytotoxicity against breast cancer cells and Fe(III) luminescent sensing

Significant enhancement of anticancer effect of iridium (III) complexes encapsulated in liposomes

Copper(II) complexes incorporated with 2,2-bipyridyl and 2,2′-(((1E,1′E)-1,4-phenylene-bis(methanylylidene))bis(azanylylidene)) diphenol derivatives: In-vitro interaction with DNA/BSA, DFT, molecular docking and cytotoxicity

Mixed-ligand copper(ii)-diimine complexes of 3-formylchromone- N 4-phenyl thiosemicarbazone: 5,6-dmp co-ligand confers enhanced cytotoxicity

Rhodium(III) and iridium(III) complexes with 1,2-naphthoquinone-1-oximate as a bidentate ligand: synthesis, structure, and biological activity

Contrasting reactivity and cancer cell cytotoxicity of isoelectronic organometallic iridium(III) complexes

Synthesis, Characterization and Anticancer Efficacy Studies of Iridium (III) Polypyridyl Complexes against Colon Cancer HCT116 Cells

Synthesis of a series of novel In(III) 2,6-diacetylpyridine bis(thiosemicarbazide) complexes: structure, anticancer function and mechanism